Research Article

Association between neutrophil–lymphocyte ratio and arterial stiffness in patients with acute coronary syndrome

Yanyan Li¹, Xiaofang Chen², Lingzhi Huang³,⁴ and Jinyang Lu⁵

¹Department of Outpatient, Xiangya Hospital, Central South University, Changsha, Hunan Province 410008, China; ²Department of Nursing, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong Province 510630, China; ³Clinical Nursing Teaching and Research Section, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province 410011, China; ⁴Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province 410011, China; ⁵Intervention Catheterization Room of Radiology Department, The Second Xiangya Hospital of Central South University, Changsha, Hunan Province 410011, China

Correspondence: Lingzhi Huang (huanglingzhi@csu.edu.cn)

The aim of the present study was to assess the association between neutrophil–lymphocyte ratio (NLR) and arterial stiffness and provide a predictive index for diagnosing atherosclerosis in patients with acute coronary syndrome (ACS). We enrolled patients with ACS who were confirmed by coronary angiography. Data were collected by questionnaire and blood indexes. Brachial-ankle pulse wave velocity (baPWV) was measured using BP-203RPE III network arteriosclerosis detection equipment. Correlation analysis of traditional cardiovascular risk factors and baPWV was performed, and multivariate line regression analysis was conducted to explore the relevant factors for baPWV. A total of 210 patients were included in the final analyses according to the inclusion criteria. Patients with a high baPWV had a lower lymphocyte count than those with a low baPWV (1.2 ± 0.4 vs. 1.4 ± 0.4, P = 0.004). The NLRs of the low and high baPWV groups were 3.1 ± 1.5 and 4.0 ± 2.1, respectively; no significant difference was observed. The results suggest that there is a positive relationship between baPWV and NLR (r = 0.403, P = 0.005) and neutrophils (r = 0.319, P = 0.016). Multivariate line regression suggested that NLR was positively associated with baPWV (B = 0.372, P = 0.000). The present results indicate that NLR is independently associated with arterial stiffness in patients with ACS. NLR, an inexpensive, easily measurable, widely available biomarker, could be an additional tool for assessing cardiovascular risk in clinical practice.

Introduction

The burden of atherosclerotic cardiovascular disease (ASCVD) has increased rapidly and substantially in China. There were approximately 2.4 million deaths from ASCVD in 2016, representing 61% of deaths from cardiovascular disease (CVD) and 25% of all deaths, which is an increase from ~1 million deaths from ASCVD (40% of deaths from CVD and 11% of all deaths) [1]. Acute coronary syndrome (ACS) is a common and severe cardiovascular and coronary heart disease (CHD) [2]. The release of inflammatory cytokines and the inflammatory response are critical pathophysiological factors [3]. Occasionally, ACS can be caused by non-atherosclerotic diseases such as arteritis, trauma, arterial dissection, thromboembolism, congenital variation, cocaine abuse, or cardiac catheterization complications. These patients usually have an abrupt onset, and the degree of risk varies. The keys to improving prognosis are early diagnosis, timely risk stratification, and reasonable clinical intervention [4].

Pulse wave velocity (PWV) is a noninvasive and simple method for accurately assessing the structure and function of arteries and vessel walls [5]. A rapid PWV shows that the degree of arterial stiffness is
strong and that the compliance of blood vessel walls is poor. A slow PWV means that the arterial vessel has a low stiffness and the vessel wall has good compliance [6,7]. Early atherosclerosis can be observed by detecting PWV. Arterial stiffness increases with decreased compliance, which can be observed before obvious symptoms appear. This method can provide a favorable opportunity for clinical treatment [8,9]. The neutrophil–lymphocyte ratio (NLR) is a biomarker that reflects the inflammation status of the human body [10] as well as the balance between activation and regulatory factors of inflammation [11]. Several studies have found that NLR is associated with malignant tumors [12], coronary artery disease [13], atherosclerosis [14], heart failure [15], acute pancreatitis [16], diabetes [17], obesity and dyslipidemia [18], hypertension [19], metabolic syndrome (MetS) and endothelial dysfunction [20], osteoporosis [21], and polycystic kidney disease [22,23]. Researchers have increasingly realized the importance of NLR in the progression of ACS. A previous study suggested that neutrophils could infiltrate at the early stage into brittle plaques such as fibrous cap, shoulder patch, middle layer of vessel, endothelial, and capillary plaques with hemorrhage. Kalay et al. found that circulating neutrophil count and NLR were associated with the severity of CHD [24]. Nilsson reported an elevated neutrophil count in lipid plaque cores from patients with CHD using coronary CT imaging [25]. However, few studies have assessed the relationship between NLR and baPWV in patients with ACS. The aim of the present study was to assess the association between NLR and arterial stiffness and provide a predictive index for diagnosing atherosclerosis in patients with ACS.

Materials and methods

Study population

We retrospectively collected the data of patients with ACS who were confirmed by coronary angiography from September 2016 to August 2017. The diagnosis of CHD was made according to the diagnostic criteria recommended by the International Heart Disease association and the diagnostic criteria for ACS recommended by the World Health Organization (WHO), American College of Cardiology/American Heart Association (ACC/AHA), and European Society of Cardiology ESC ACSs [26,27]. ACS can describe chest pain felt during a heart attack, while at rest, or when doing light physical activity. The ST segment changes and persists for more than 20 min after taking nitroglycerin. Coronary angiography shows that coronary stenosis was >50% (unstable angina) in at least one primary coronary artery. The criteria for acute myocardium infarction were as follows: troponin was typically elevated and gradually decreased with at least one of the following items: (1) typical symptoms of myocardial ischemia (clinically, chest pain), severe dyspnea, and shock; (2) electrocardiogram showing pathological Q wave or ST segment elevation/downward movement; and (3) coronary angiography or imaging showing vascular stenosis. The exclusion criteria were diabetes, hypertension, stroke, artery thrombosis, phlebitis, tumor, acute and chronic infection, trauma, and severe liver and kidney dysfunction.

The study was approved by the Ethics Committee of The Third Affiliated Hospital of Southern Medical University (2018060032). The participants of the study were informed of the study aim and that the whole process would not have privacy disclosure. The research was carried out in accordance with the World Medical Association Declaration of Helsinki, and all subjects provided written informed consent.

Demographic data

Demographic data were obtained using a standard questionnaire. The following information was collected: age, sex, body mass index (BMI), history of smoking, and history of diabetes. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured, and mean arterial pressure (MAP) was calculated using the following formula: MAP = (SBP + 2DBP)/3.

Biochemical measurements

Biochemical parameters were measured using an automated Beckman Coulter LH-750 Hematology Analyzer (Beckman Coulter, Inc., Fullerton, CA, U.S.A.). Hemoglobin, microalbuminuria, total cholesterol, total triglyceride, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), blood urea nitrogen (BUN), uric acid, estimated glomerular filtration rate (eGFR), high-sensitivity C-reactive protein (hsCRP), white blood cell (WBC), red blood cell, neutrophils, lymphocytes, and NLR were measured. Patient general characteristics were determined using a standard questionnaire administered by a group of trained investigators. Urine microalbuminuria concentrations were measured using the immunoturbidimetric method. BMI was calculated as weight (kg) divided by height squared (m²). eGFR was calculated using the formula: 186 × SCr−1.154 × age in years−0.203 × 1.210 (if black) × 0.742 (if female) [28]. MAP was calculated as one-third SBP and two-thirds DBP. Two experienced
physicians conducted coronary arteriography to detect coronary stenosis, and quantitative assessments followed the Gensini accumulated method.

**Examination of arterial stiffness**
Brachial-ankle pulse wave velocity (baPWV) was used to evaluate arterial stiffness after hospital admission. Patients rested for 15 min without smoking in a quiet room at an appropriate temperature before testing. Then, baPWV was measured using an Omron waveform analyzer (BP-203RPE III) by placing oscillometric sensors at the ends of the arms and ankle. Each study subject was tested twice, and the mean of the two results was recorded. The normal reference range for baPWV is $<1400$ cm/s, and a baPWV $>1400$ cm/s indicates increased arterial stiffness [29].

**Statistical analysis**
The study population was divided into high and low baPWV groups. Continuous variables were expressed as means and standard deviations if the data had a normal distribution, and $t$ tests were used. For continuous variables with a non-normal distribution, non-parametric tests were used. Classification data were expressed as percentages and counts, and two groups were compared using chi-square tests. Pearson's correlation coefficient was used to assess the relationship between baPWV and quantitative parameters, and Spearman's correlation coefficient was used to assess baPWV and qualitative data. A partial correlation coefficient was also calculated between baPWV and NLR with adjusted potential factors. Multivariate line regression analysis was conducted to explore the relevant factors for baPWV. baPWV was treated as the dependent variable and age, sex, BMI, smoking, diabetes, MAP, hemoglobin, microalbuminuria, total cholesterol, total triglyceride, eGFR, hsCRP, WBC, red blood cell, neutrophils, lymphocytes, and NLR were independent variables. All statistical analyses were performed using SPSS 22.0 software version, and $P < 0.05$ was considered statistically significant.

**Results**
A total of 210 patients were included in the final analyses according to the inclusion criteria; 120 and 90 patients in the low and high baPWV groups, respectively. The age of the study population ranged from 36 to 65, with a mean of 57.1 years. The mean ages of the low and high baPWV groups were $52.3 \pm 14.6$ and $63.6 \pm 11.8$, respectively. The percentage of female patients in the low baPWV group was 50%, compared with 60% in the high baPWV group. The NLR of the low group was $3.1 \pm 1.5$, compared with $4.0 \pm 2.1$ in the high baPWV group; this difference was statistically significant. Compared with the low baPWV group, patients in the high baPWV group tended to be older ($63.6 \pm 11.8$ vs. $52.3 \pm 14.6$, $P < 0.001$), have a higher BMI ($22.1 \pm 3.4$ vs. $20.8 \pm 4.1$, $P = 0.015$), have more diabetes ($30.0\%$ vs. $10.0\%$, $P = 0.002$), and elevated SBP and MAP levels ($P = 0.026$ and $P = 0.019$, respectively). Total cholesterol and uric acid levels were higher ($P = 0.000$ and $P = 0.002$, respectively) and the lymphocyte count was lower ($P = 0.004$) in the control group. No significance differences were found in other parameters (Table 1).

The correlations between baPWV and other parameters in patients with ACS are presented in Table 2. There was an obvious positive relationship between baPWV and NLR ($r = 0.403$, $P = 0.005$) and neutrophils ($r = 0.319$, $P = 0.016$). There was a negative correlation between baPWV and lymphocyte count ($r = -0.206$, $P = 0.030$). Age, smoking, diabetes, SBP, MAP, hs-CRP, LDL-C, uric acid, and WBC were positively correlated with baPWV (Table 2). The partial correlation coefficient between baPWV and NLR via adjusting potential factors was $0.398$ ($P = 0.013$).

Multivariate line regression analysis was performed by treating baPWV as the dependent variable and age, sex, BMI, smoking, diabetes, MAP, hemoglobin, microalbuminuria, total cholesterol, total triglyceride, eGFR, hsCRP, WBC, red blood cell, neutrophils, lymphocytes, and NLR as independent variables. The results suggested that NLR was positively associated with baPWV ($B = 0.372, P = 0.000$). baPWV increased by 0.372 when NLR changed by a unit. In addition, age, SBP, BMI, total cholesterol, and uric acid were related to baPWV ($B = 0.517, P = 0.000; B = 0.462, P = 0.001; B = 0.499, P = 0.003; B = 2.530, P = 0.022; and B = 3.381, P = 0.000$, respectively) (Table 3).

**Discussion**
The present study found that patients in the high baPWV group had an increased NLR compared with those in the low baPWV group. Multivariate line regression analysis suggested that NLR was an independent predictor of baPWV in patients with ACS.

Atherosclerosis is the pathological basis of macrovascular diseases, and neutrophils are a key factor in the inflammatory response. On the one hand, neutrophils can strengthen inflammatory reactions by increasing macrophage and antigen levels. On the other hand, neutrophils participate in acute tissue damage by secreting inflammatory mediators [30]. For example, neutrophils release arachidonic acid derivatives and superoxide radicals by proteolytic
enzymes, which make the formed plaques more fragile. Activated neutrophils also adhere to the endothelial cell surface and cause endothelial cell dysfunction. During this process, the up-regulation of pro-inflammatory factors further aggravates vascular inflammation, and long-term inflammation leads to vascular smooth muscle proliferation, microvascular formation, and subsequent arteriosclerosis [31]. Previous studies found that platelet-induced inflammatory responses played a key role in the formation of atherosclerosis. Activated platelets can release inflammatory mediators and mitotic substances into the local microenvironment [31], which recruit more platelets and WBCs to the inflammatory sites such as platelet C3a and C5a-induced inflammatory factor-17. This process could accelerate arteriosclerosis [32]. Because the total number of plasma lymphocytes in patients with ACS decreased and the CD4/CD8 ratio decreased significantly, the decline in the number of lymphocytes reduced the body's anti-inflammatory ability, creating a short-term inflammatory status [33]. Therefore, some studies reported that lymphopenia could be associated with the progress of arteriosclerosis.

NLR reflects the ratio of neutrophils to lymphocytes. The current results suggest that baPWV was significantly associated with BMI and total cholesterol, despite no significant correlations between baPWV and BMI and total cholesterol. There was no significant difference in neutrophils between the high and low baPWV groups, whereas the lymphocyte count was decreased significantly in the high baPWV group compared with the low baPWV group. It is possible that the increase in NLR was caused by the decreased lymphocyte count, which is consistent with a report by Solak et al. [34]. NLR can also reflect the stability of the WBC count, and cannot be affected by changes in acute state. Patients with ACS usually have varying inflammatory statuses, and so blood cells can affect atherosclerosis in different ways [35]. A previous study found that in the inflammatory state, neutrophils are an important regulatory factor in the progression of tissue damage to the arterial wall. Lymphocyte apoptosis further increased artery hardening [36]. In addition, low lymphocyte levels may be associated with malnutrition, and neutrophil and lymphocyte counts were

Table 1 General characteristics between two groups

| Factors                | Low baPWV (n = 120) | High baPWV (n = 90) | t/χ²/u | P      |
|------------------------|---------------------|---------------------|--------|--------|
| Age (year)             | 52.3 ± 14.6         | 63.6 ± 11.8         | 6.014  | <0.001 |
| Sex (female%)          | 60 (50.0)           | 54 (60.0)           | 2.072  | 0.150  |
| BMI (kg/m²)            | 20.8 ± 4.1          | 22.1 ± 3.4          | 2.443  | 0.015  |
| Smoking (%)            | 30 (25.0)           | 24 (26.7)           | 0.074  | 0.784  |
| Diabetes (%)           | 12 (10.0)           | 27 (30.0)           | 13.603 | 0.002  |
| Total triglyceride (mmol/L) | 1.7                 | 1.0                 |       |        |
| Total cholesterol (mmol/L) | 5.3                 | 5.6                 |       |        |
| baPWV (cm/s)           | 1646.4 ± 220.6      | 2476.2 ± 588.2      | 14.189 | <0.001 |
| Microalbuminuria (g/L) | 104.3 ± 24.6        | 99.7 ± 18.9         | 1.477  | 0.141  |
| Total cholesterol (mmol/L) | 5.3 ± 1.2           | 4.7 ± 1.0           | 3.866  | 0.000  |
| Total triglyceride (mmol/L) | 1.7 ± 0.9           | 1.6 ± 0.0           | 0.026  | 0.536  |
| HDL-C (mmol/L)         | 1.57 ± 0.4          | 1.53 ± 0.4          | 0.035  | 0.972  |
| LDL-C (mmol/L)         | 3.6 ± 0.8           | 3.74 ± 0.8          | 1.222  | 0.902  |
| Uric acid (mmol/L)     | 312.6 ± 49.6        | 333.4 ± 46.9        | 3.077  | 0.002  |
| Hemoglobin (g/L)       | 10.9 ± 5.0          | 10.8 ± 5.0          | 0.149  | 0.798  |
| HbA1c (%)              | 8.6 ± 6.2           | 8.5 ± 6.2           | 0.000  | 0.999  |
| hsCRP (mg/dl)          | 1.2 (0.8–4.1)       | 4.7 (0.7–10.6)      | 2.367  | 0.345  |
| NLR                    | 3.1 ± 1.5           | 4.0 ± 2.1           | 3.622  | 0.000  |
| Lymphocyte (%)         | 14.6 ± 63.6         | 15.4 ± 69.1         | 1.572  | 0.117  |
| Other                  | 60 (50.0)           | 54 (60.0)           | 2.072  | 0.150  |
| ST-S+ (STEMI)          | 31 (25.8)           | 23 (25.8)           | 0.157  | 0.924  |
| NSTEMI                 | 30 (25.0)           | 20 (22.2)           |       |        |
| ACS                    | 7.9 ± 69.1          | 8.6 ± 69.1          |       |        |
| Heart rate (n)         | 67.3 ± 7.9          | 69.1 ± 8.6          | 1.572  | 0.117  |
| Age (year)             | 52.3 ± 14.6         | 63.6 ± 11.8         | 6.014  | <0.001 |
| Sex (female%)          | 60 (50.0)           | 54 (60.0)           | 2.072  | 0.150  |
| BMI (kg/m²)            | 20.8 ± 4.1          | 22.1 ± 3.4          | 2.443  | 0.015  |
| Smoking (%)            | 30 (25.0)           | 24 (26.7)           | 0.074  | 0.784  |
| Diabetes (%)           | 12 (10.0)           | 27 (30.0)           | 13.603 | 0.002  |
| Total triglyceride (mmol/L) | 1.7                 | 1.0                 |       |        |
| Total cholesterol (mmol/L) | 5.3                 | 5.6                 |       |        |
| baPWV (cm/s)           | 1646.4 ± 220.6      | 2476.2 ± 588.2      | 14.189 | <0.001 |
| Microalbuminuria (g/L) | 104.3 ± 24.6        | 99.7 ± 18.9         | 1.477  | 0.141  |
| Total cholesterol (mmol/L) | 5.3 ± 1.2           | 4.7 ± 1.0           | 3.866  | 0.000  |
| Total triglyceride (mmol/L) | 1.7 ± 0.9           | 1.6 ± 0.0           | 0.026  | 0.536  |
| HDL-C (mmol/L)         | 1.57 ± 0.4          | 1.53 ± 0.4          | 0.035  | 0.972  |
| LDL-C (mmol/L)         | 3.6 ± 0.8           | 3.74 ± 0.8          | 1.222  | 0.902  |
| Uric acid (mmol/L)     | 312.6 ± 49.6        | 333.4 ± 46.9        | 3.077  | 0.002  |
| Hemoglobin (g/L)       | 10.9 ± 5.0          | 10.8 ± 5.0          | 0.149  | 0.798  |
| HbA1c (%)              | 8.6 ± 6.2           | 8.5 ± 6.2           | 0.000  | 0.999  |
| hsCRP (mg/dl)          | 1.2 (0.8–4.1)       | 4.7 (0.7–10.6)      | 2.367  | 0.345  |
| NLR                    | 3.1 ± 1.5           | 4.0 ± 2.1           | 3.622  | 0.000  |
| Lymphocyte (%)         | 14.6 ± 63.6         | 15.4 ± 69.1         | 1.572  | 0.117  |
| Other                  | 60 (50.0)           | 54 (60.0)           | 2.072  | 0.150  |
| ST-S+ (STEMI)          | 31 (25.8)           | 23 (25.8)           | 0.157  | 0.924  |
| NSTEMI                 | 30 (25.0)           | 20 (22.2)           | 0.157  | 0.924  |
| ACS                    | 7.9 ± 69.1          | 8.6 ± 69.1          | 1.572  | 0.117  |

STEMI: St-segment elevation myocardial infarction; NSTEMI: non-St-segment elevation myocardial infarction.
Table 2 Correlation analysis between factors and baPWV

| Factors            | r    | P     |
|--------------------|------|-------|
| Age (year)         | 0.786| <0.001 |
| BMI (kg/m²)        | −0.193| 0.434 |
| Smoking (%)        | 0.361*| 0.002 |
| Diabetes (%)       | 0.431*| 0.004 |
| Hypertension (%)   | 0.138| 0.612 |
| SBP (mmHg)         | 0.512| 0.021 |
| DBP (mmHg)         | 0.108| 0.681 |
| Heart rate (n)     | 0.115| 0.593 |
| MAP (mmHg)         | 0.354| 0.015 |
| Hemoglobin (g/L)   | −0.076| 0.521 |
| Microalbuminuria (g/L) | −0.421| 0.006 |
| Total cholesterol (mmol/L) | −0.186| 0.196 |
| Total triglyceride (mmol/L) | −0.095| 0.403 |
| HDL-C (mmol/L)     | −0.123| 0.361 |
| LDL-C (mmol/L)     | 0.201| 0.042 |
| Uric acid (mmol/L) | 0.623| 0.000 |
| BUN (mmol/L)       | 0.034| 0.726 |
| rGFR (ml/min/1.73 m²) | 0.168| 0.072 |
| hsCRP (mg/dl)      | 0.305| 0.007 |
| WBC (×10⁹/mm³)     | 0.291| 0.035 |
| Red blood cell (×10¹²/L) | 0.107| 0.367 |
| Neutrophils (×10⁹/mm³) | 0.319| 0.016 |
| Lymphocyte (×10³/mm³) | −0.206| 0.030 |
| NLR                | 0.403| 0.006 |

*Spearman correlation coefficient.

Table 3 Multivariate line regression of relevant affecting baPWV*

| Factors            | B    | SE    | t     | P     |
|--------------------|------|-------|-------|-------|
| Age                | 0.517| 0.496 | 6.387 | 0.000 |
| SBP                | 0.462| 0.130 | 3.445 | 0.001 |
| NLR                | 0.372| 3.120 | 7.384 | 0.000 |
| BMI                | 0.499| 0.178 | 2.982 | 0.003 |
| Total cholesterol  | 2.530| 1.098 | 2.304 | 0.022 |
| Uric acid          | 3.381| 0.481 | 8.071 | 0.000 |

*Adjusted R² = 0.432.

significantly associated with PWV in patients with hematologic malignancies [37]. The comprehensive analysis above shows that reduced lymphocyte levels and elevated neutrophil levels both predict the severity of arteriosclerosis in different ways.

The main difference between the present study and the previous report is that the present study was conducted in patients with ACS. The present study has several limitations. First, it was conducted in patients with ACS, and so caution must be used when applied to other population settings. Second, the present study had a cross-sectional design, and thus a cause–effect relationship cannot be determined. Third, the present study did not define the pathology mechanism. Finally, some parameters such as creatine kinase, creatine kinase-MB, and cardiac troponin I were not included in the analysis, and these parameters may affect the results. Therefore, further studies are needed.

In conclusion, the present results demonstrated that NLR was independently associated with arterial stiffness in patients with ACS. NLR, an inexpensive, easily measurable, widely available biomarker, could be an additional tool for assessing cardiovascular risk in clinical practice. However, further prospective studies are needed to confirm a cause-and-effect relationship.

© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
Acknowledgments
We thank all our colleagues working in the Third Affiliated Hospital of Southern Medical University.

Author Contribution
LYY and HLZ conceived and designed the research; CXF collected and analyzed the data; LJY created all tables and figures; LYY and HLZ drafted the manuscript; LYY made critical revision of the manuscript; all authors read and approved the final manuscript.

Funding
The authors declare that there are no sources of funding to be acknowledged.

Competing Interests
The authors declare that there are no competing interests associated with the manuscript.

Abbreviations
ACS, acute coronary syndrome; ASCVD, atherosclerotic cardiovascular disease; baPWV, brachial-ankle pulse wave velocity; BMI, body mass index; BUN, blood urea nitrogen; CHD, coronary heart disease; DBP, diastolic blood pressure; GFR, glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; MAP, mean arterial pressure; NLR, neutrophil–lymphocyte ratio; SBP, systolic blood pressure; WBC, white blood cell.

References
1 Zhao, D., Liu, J., Wang, M., Zhang, X. and Zhou, M. (2019) Epidemiology of cardiovascular disease in China: current features and implications. Nat. Rev. Cardiol. 16, 203–212
2 Katus, H., Ziegler, A., Ekinci, O., Giannitsis, E., Stough, W.G., Achenbach, S. et al. (2017) Early diagnosis of acute coronary syndrome. Eur. Heart J. 38, 3049–3055, https://doi.org/10.1093/eurheartj/ehx492
3 Martshevich, S.Y., Semenova, Y.V., Kutshenko, N.P., Zagrebelsky, A.V. and Ginzburg, M.L. (2017) Awareness of cardiovascular disease, its risk factors, and its association with attendance at outpatient clinics in acute coronary syndrome patients. Integr. Med. Res. 6, 240–244, https://doi.org/10.1016/j.imr.2017.06.003
4 Mavroudis, C.A., Elefteriou, D., Hong, Y., Majumder, B., Koganti, S., Sapsford, R. et al. (2017) Microparticles in acute coronary syndrome. Thromb. Res. 156, 109–116, https://doi.org/10.1016/j.thromres.2017.06.003
5 Hermeling, E., Reesink, K.D., Hoeks, A.P. and Reneman, R.S. (2010) Potentials and pitfalls of local PWV measurements. Am. J. Hypertens. 23, 934–935, https://doi.org/10.1038/ajh.2010.123
6 Lu, Y.C., Lyu, P., Zhu, H.Y., Xu, D.X., Tahir, S., Zhang, H.F. et al. (2018) Brachial-ankle pulse wave velocity compared with mean arterial pressure and pulse pressure in risk stratification in a Chinese population. J. Hypertens. 36, 528–536, https://doi.org/10.1097/JHJ.0000000000001591
7 Nabeel, P.M., Karthik, S., Joseph, J. and Palliat. Med. https://doi.org/10.1016/j.ijcard.2014.06.098
8 Inomoto, A., Fukuda, R., Deguchi, J. and Toyonaga, T. (2017) Relation between respiratory function and arterial stiffness assessed using brachial-ankle pulse wave velocity changes during cuff induced hyperemia. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2017, 1700–1703
9 Haybar, H., Ahmadzadeh, A., Assareh, A., Afshari, N., Bozorgmanesh, M. and Vakili, M. (2016) Intermediate-risk chronic stable angina: neutrophil–lymphocyte ratio and fibrinogen levels improved predicting angiographically-detected coronary artery disease. Clin. Exp. Nephrol. 22, 173–178, https://doi.org/10.1007/s10157-017-1464-2
10 Kaya, M.G. (2013) Inflammation and coronary artery disease: as a new biomarker neutrophil/lymphocyte ratio. Turk. Kardiyol. Dern. Ars. 41, 191–192, https://doi.org/10.5543/tdka.2013.84484
11 Wagdy, S., Sobhy, M. and Loufti, M. (2016) Neutrophil/lymphocyte ratio as a predictor of in-hospital major adverse cardiac events, new-onset atrial fibrillation, and no-reflow phenomenon in patients with ST elevation myocardial infarction. Clin. Insights Cardioiol. 10, 19–22, https://doi.org/10.4137/CMC.S35555
12 Ahn, H.K., Hwang, I.C., Lee, J.S., Sym, S.J., Cho, E.K. and Shin, D.B. (2016) Neutrophil–lymphocyte ratio predicts survival in terminal cancer patients. J. Palliat. Med. 19, 437–441, https://doi.org/10.1089/jpm.2015.0277
13 Haybar, H., Ahmadzadeh, A., Assareh, A., Afshari, N., Bozorgmanesh, M. and Vakili, M. (2016) Intermediate-risk chronic stable angina: neutrophil–lymphocyte ratio and fibrinogen levels improved predicting angiographically-detected coronary artery disease. Iran Red. Crescent Med. J. 18, e18570, https://doi.org/10.5812/rcmj.18570
14 Balta, S., Ozturk, C., Yildirim, A.O., Erdogan, S. and Celik, T. (2016) The neutrophil–lymphocyte ratio and atherosclerosis. Expert Rev. Cardiovasc. Ther. 14, 885, https://doi.org/10.1080/14779072.2016.1194199
15 Balta, S., Demirkol, S., Aparci, M., Celik, T. and Ozturk, C. (2014) The neutrophil lymphocyte ratio in coronary heart disease. Int. J. Cardiol. 176, 267, https://doi.org/10.1016/j.ijcard.2014.06.098
16 Suppiah, A., Malde, D., Arab, T., Hamed, M., Algar, V., Smith, A.M. et al. (2013) The prognostic value of the neutrophil–lymphocyte ratio (NLR) in acute pancreatitis: identification of an optimal NLR. J. Gastrointest. Surg. 17, 675–681, https://doi.org/10.1007/s11605-012-2121-1
17 Ayhan, H., Kasapkara, H.A., Aslan, A.N., Durmaz, T., Keles, T., Akcay, M. et al. (2015) Relationship of neutrophil-to-lymphocyte ratio with aortic stiffness in Type 1 Diabetes mellitus. Can. J. Diabetes 39, 317–321, https://doi.org/10.1016/j.jcjd.2015.01.004

18 Nam, S.H., Kang, S.G. and Song, S.W. (2017) The neutrophil–lymphocyte ratio is associated with coronary artery calcification in asymptomatic Korean males: a cross-sectional study. Biomed. Res. Int. 2017, 1989417, https://doi.org/10.1155/2017/1989417

19 Karahan, B., Altun, S., Sevko, A.A., Kakar, M., Nahari, I., Demirkol, S. et al. (2013) The comparative effects of valsartan and amiodipine on WVF levels and N/V ratio in patients with newly diagnosed hypertension. Clin. Exp. Hypertens. 35, 516–522, https://doi.org/10.3109/0641963.2012.758734

20 Balta, S., Kurtoglu, E., Kucuk, U., Demirkol, S. and Ozturk, C. (2014) Neutrophil–lymphocyte ratio as an important assessment tool. Expert Rev. Cardiavasc. Ther. 12, 537–538, https://doi.org/10.1586/14779072.2014.902309

21 Yu, X.Y., Li, X.S., Li, Y., Liu, T. and Wang, R.T. (2015) Neutrophil–lymphocyte ratio is associated with arterial stiffness in postmenopausal women with osteoporosis. Arch. Gerontol. Geriatr. 61, 76–80, https://doi.org/10.1016/j.archger.2015.03.011

22 Gul, C.B., Yildiz, A., Erozy, A., Kahvecioğlu, S., Asilis, B., Yildirim, F. et al. (2015) Correlation between arterial stiffness and inflammatory markers in autosomal dominant polycystic kidney disease patients with preserved renal function. Int. Urol. Nephrol. 47, 1187–1194, https://doi.org/10.1007/s11255-015-1022-0

23 Mozos, I., Malaiiner, C., Horbaczuk, J., Guç, G., Stoian, D., Luca, C.T. et al. (2017) Inflammatory markers for arterial stiffness in cardiovascular diseases. Front. Immunol. 8, 1058, https://doi.org/10.3389/fimmu.2017.01058

24 Kalay, N., Dogdu, O., Koc, F., Yarioglues, M., Ardic, I. et al. (2012) Hematologic parameters and angiographic progression of coronary atherosclerosis. Angiology 63, 213–217, https://doi.org/10.1177/0003319711412763

25 Nilsson, L., Wieringa, W.G., Pudziute, G., Gjerde, M., Engvall, J., Swahn, E. et al. (2014) Neutrophil/lymphocyte ratio is associated with non-calcified plaque burden in patients with coronary artery disease. PLoS One 9, e108183, https://doi.org/10.1371/journal.pone.0108183

26 Gibbons, R.J., Abrams, J., Chatterjee, K., Daley, J., Deedwania, P.C., Douglas, J.S. et al. (2003) ACC/AHA 2002 guideline update for the management of patients with chronic stable angina–summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J. Am. Coll. Cardiol. 41, 159–168, https://doi.org/10.1016/S0735-1097(02)02848-6

27 Roffi, M., Patrono, C., Collet, J.P., Mueller, C., Valgimigli, M., Andreotti, F. et al. (2016) 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 37, 267–315, https://doi.org/10.1093/eurheartj/ehv320

28 Farrington, K., Nistor, I., Acuella, F., Clyne, N., De Vo, L. et al. (2017) Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m2): a summary document from the European Renal Best Practice Group. Nephrol. Dial. Transplant. 32, 9–16

29 Yamashina, A., Tomiyama, H., Arai, T., Hiro, K., Koji, Y., Hirayama, Y. et al. (2003) Brachial-ankle pulse wave velocity as a marker of atherosclerotic vascular damage and cardiovascular risk. Hypertens. Res. 26, 615–622

30 Soehnlein, O. (2012) Multiple roles for neutrophils in atherosclerosis. Circ. Res. 110, 875–888, https://doi.org/10.1161/CIRCRESAHA.111.257535

31 Nording, H.M., Seizer, P. and Langer, H.F. (2014) Platelets in inflammation and atherogenesis. Front. Immunol. 6, 98, https://doi.org/10.3389/fimmu.2015.00098

32 Khan, M.A. and Nicolits, M.R. (2013) Complement-mediated microvascular injury leads to chronic rejection. Adv. Exp. Med. Biol. 735, 233–246, https://doi.org/10.1007/978-1-4614-1181-2_16

33 Major, A.S., Fausto, S. and Linton, M.F. (2002) B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. Arterioscler. Thromb. Vasc. Biol. 22, 1892–1898, https://doi.org/10.1161/01.ATV.0000039169.47943.EE

34 Solak, Y., Yilmaz, M.I., Sonmez, A., Saglam, M., Cakir, E., Unal, H.U. et al. (2013) Neutrophil to lymphocyte ratio independently predicts cardiovascular events in patients with chronic kidney disease. Clin. Exp. Nephrol. 17, 532–540, https://doi.org/10.1007/s10157-012-0728-x

35 Baetta, R. and Corsini, A. (2010) Role of polymorphonuclear neutrophils in atherosclerosis: current state and future perspectives. Atherosclerosis 210, 1–13, https://doi.org/10.1016/j.atherosclerosis.2009.10.028

36 Nunez, J., Sanchis, J., Bodi, V., Nunez, E., Mainar, L., Heatt, A.M. et al. (2009) Relationship between low lymphocyte count and major cardiac events in patients with acute chest pain, a non-diagnostic electrocardiogram and normal troponin levels. Atherosclerosis 206, 251–257, https://doi.org/10.1016/j.atherosclerosis.2009.01.029

37 Mozos, I., Borzaiz, G., Caraba, A. and Mihaescu, R. (2017) Arterial stiffness in hematologic malignancies. Onco Targets Ther. 10, 1381–1388, https://doi.org/10.2147/OTT.S126852